Strengthening Oligonucleotide Capabilities: Zelmic Invests in Advanced UHPLC Technology
Zelmic continues to expand its capabilities in advanced topical and transdermal drug development with a strategic investment in state-of-the-art analytical instrumentation: the Vanquish™ Horizon UHPLC System (integrated biocompatible system). This investment marks an important step in supporting the growing demand for oligonucleotide-based therapeutics, including siRNA and other nucleic acid modalities. Enabling the Next Generation of…
Continue Reading
